| P597 | Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA | Nicola E. Annels, PhD; Guy R. Simpson; Hardev S. Pandha, PhD, FRCP, FRACP, FR; Mehreen Arif; Kevin Harrington, MD; Alan Melcher; Richard Vile, PhD | Checkpoint blockade; Dendritic cell; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P598 | Discovery and preclinical development of E7766, a novel STING agonist for cancer immunotherapy with a superior profile over a leading reference compound | Xingfeng Bao, Ph.D; Kuan-Chun Huang, Ph.D.; Atsushi Endo; Dinesh Chandra, PhD; Jiayi Wu; Dae-Shik Kim; Diana Albu; Karen Tendyke; Kara Loiacono; Thomas A. Noland, Jr, PhD; Christy Ingersoll; David Verbel, MPH; Rongrong Jiang; Donna Kolber-Simonds; Chi Zhang; Muzaffar Akram, MSc., MA; Minghong Hao; HyeongWook Choi; Vaishali Dixit; Janna Hutz, PhD; John Wang; Frank Fang | Antigen presenting cells; Genetic polymorphism; T cell; Tumor microenvironment |
| P599 | OncoVEXmGM-CSF in combination with checkpoint inhibition leads to tumor-specific systemic immunity and increased tumor antigen response in a murine syngeneic melanoma model | Keegan Cooke, BS; Juan Estrada; Petia Mitchell; Jinghui Zhan; Jing Qing; Jude Canon; Pedro J. Beltran | Checkpoint blockade; Neoantigens; T cell; Tumor antigens |
| P600 | IL12/IL15 and PD-L1 blocker co-expressing oncolytic herpes virus VG161 significantly alters tumor microenvironment and eliminates prostate tumors in animal models | Zahid Delwar, PhD; Neetu Saxena, PhD; Erica Lee, PhD; Morgan E. Roberts, PhD; Luke Bu, M.Sc.; Guoyu Liu, MD; Yanal Murad, PhD; Jun Ding, PhD; Dmitry Chouljenko, PhD; Igor Moskalev; Syam Somasekharan, PhD; Ronghua Zhao, MD; Paul Rennie, PhD; William Jia, PhD | Adoptive immunotherapy; Checkpoint blockade; Cytokine; Gene expression; Immune monitoring; Regulatory T cell (Treg cell); Stem cell/cancer-initiating cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P601 | STING signaling can enhance melanoma antigenicity | Rana Falahat, PhD; Adam W. Mailloux, PhD; Patricio Perez-Villarroel; Genyuan Zhu, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; James J. Mulé, PhD; | Adoptive immunotherapy; Cytokine; Immune adjuvant; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor evasion; Tumor microenvironment |
| P602 | Generation and characterization of a CTLA-4 antibody with improved FcgammaR-dependent Treg deletion for tumor microenvironment-targeted oncolytic virotherapy of cancer | Bjorn Frendeus, PhD; Monika Semmrich, PHD; Monika Semmrich, PHD; Jean-Baptiste jb. Marchand, pHD; Petra Holmkvist; Linda Mårtensson; Ulla-Carin Tornberg; Ingrid Teige; Andres McAllister; Eric Quemeneur, PharmD, PhD; Bjorn Frendeus, PhD; Nathalie Silvestre | Checkpoint blockade; Coinhibition; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P603 | Novel treatment strategy for peritoneal carcinomatosis: adoptive cell transfer of tumor-specific lymphocytes after dual therapy with oncolytic virus and PD-1 blockade | Esther Giehl, MD; David Bartlett, MD; Zong Sheng Guo, PhD; Mathilde Feist, MD; | Adoptive immunotherapy; Checkpoint blockade; T cell |
| P604 | DNA-based delivery of immunomodulatory antibodies is effective both in muscle and tumor despite distinct pharmacokinetics | Liesl Jacobs, MPharm; Elien De Smidt; Nick Geukens; Paul Declerck; Kevin Hollevoet, PhD | Antibody; Checkpoint blockade; Targeted therapy |
| P605 | Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas | Hong Jiang, PhD; Dong Ho Shin; Caroline Carrillo, BS; Verlene Henry, BS; Teresa Nguyen, BS; Yisel A. Rivera-Molina, PhD; Frederick Lang, MD; Candelaria Gomez-Manzano, MD; Juan Fueyo | Costimulation; Gene expression; Immune contexture; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P606 | IFN gamma-independent upregulation of PD-L1 in oHSV-1 infected tumour cells | Erica Lee, PhD; Jun Ding, PhD; Sheng Yu; Yanal Murad, PhD; Dmitry Chouljenko, PhD; Guoyu Liu, MSc, MD; Zahid Delwar, PhD; Luke Bu, M.Sc.; Will Liu, PhD; Ronghua Zhao, MD; William Jia, PhD | Checkpoint blockade; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P607 | The TLR4 agonist G100 enhances the efficacy of adoptive T-cell therapy | Jardin Leleux, PhD; Tina C. Albershardt, PhD; Peter Berglund, PhD; Jan H. Ter Meulen, MD, PhD | Adoptive immunotherapy; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P608 | ProTriTAC: a protease-activatable T cell engager platform that links half-life extension to functional masking and expands therapeutic window to enable targeting of broadly expressed tumor antigens | S. Jack Lin, PhD; Maria Rosalyn Dayao; Kendrick J. Kim; Sony S. Rocha; Kathryn Kwant, PhD; Timothy Yu; Thomas Evans; Stephen Yu; Michael Cremin; Wade Aaron, BS; Maria Gamez-Guerrero; Evan Callihan; Golzar Hemmati; Kevin J. Wright, PhD; Yinghua Xiao, Master Degree; Manasi Barath; Che-Leung Law, PhD; Bryan Lemon, PhD; Richard Austin, PhD; Holger Wesche, PhD | Antibody; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Tumor stroma |
| P609 | First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells | Boris Minev, MD; Elliot Lander, MD; John F. Feller, MD; Mark Berman, MD; Stuart May, MD; Bernadette Greenwood; Ivelina Minev, MSc; Duong Nguyen, PhD; Antonio F. Santidrian; Dobrin Draganov, PhD; Mehmet O. Kilinc, PhD; Santosh Kesari, MD, PhD; Edward McClay, MD; Gabriel Carabulea, MD; Aladar Szalay, PhD; | Clinical trial; Cytokine; Immune monitoring; Leukemia/Lymphoma; MDSC; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| P610 | Transcriptome analysis of CT26 tumors treated with HSV-1 oncolytic virus expressing multiple immune factors | Yanal Murad, PhD; Jun Ding, PhD; Erica Lee, PhD; Dmitry Chouljenko, PhD; Luke Bu, M.Sc.; Guoyu Liu, MSc, MD; Zahid Delwar, PhD; Will Liu, PhD; Ronghua Zhao, MD; William Jia, PhD | Tumor microenvironment |
| P611 | Single shot intravenous oncolytic vesicular stomatitis virus therapy promotes intratumoral CD8+ T-cell infiltration and enhances therapeutic response to checkpoint blockade | Shruthi Naik, PhD; Kah Whye Peng, PhD; Stephen J. Russell, MD, PhD | Biomarkers; Checkpoint blockade; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P612 | Overcoming oncolytic poliovirus-mediated adaptive immune resistance by combining with anti-PD1/-PDL1 therapy in cancer. | Smita Nair, PhD; Eda Holl, PhD, RAC; Michael Brown, PhD; Victoria Frazier; David Boczkowski, BS, MSc; Vidyalakshmi Chandramohan, PhD; Darell D. Bigner, MD, PhD; Shelley Hwang; Matthias Gromeier, MD; | Checkpoint blockade; Immune adjuvant; Inflammation; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P613 | Non-oncolytic viral infection reduces tumor burden and promotes anti-tumor immunity in synergy with checkpoint blockade | Jenna Newman; Charles B. Chesson, PhD; Andrew Zloza | Checkpoint blockade; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P614 | Nano-Pulse Stimulation™ of murine melanoma and mammary carcinoma is a physical modality that eliminates the treated tumor by regulated cell death and induces innate and adaptive immune responses | Richard Nuccitelli, MS, PhD; Amanda McDaniel, BA; Bruce Freimark, PhD; Joel Benjamin, PhD; Jessica Sood, BS; Darrin Uecker, MS; | Biomarkers; Gene expression; Immune monitoring; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P615 | Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment | Eric Quemeneur, PharmD, PhD; Jean-Baptiste jb. Marchand, pHD | Immune contexture; Immune suppression; Regulatory T cell (Treg cell); Tumor microenvironment |
| P616 | Fueling antitumor immunity using oncolytic viruses encoding metabolic modulators | Dayana B. Rivadeneira, PhD; Kristin DePeaux; Nicole E. Scharping, BS; Padmavathi Sampath, PhD; Saumendra Sarkar, PhD; Stephen H. Thorne, PhD; Greg M. Delgoffe, PhD | Metabolism; T cell; Tumor infiltrating lymphocytes (TILs) |
| P617 | A cell-based platform to protect and enhance oncolytic virus therapies | Antonio F. Santidrian; Dobrin Draganov, PhD; Duong Nguyen, PhD; Okyay Kilinc; Ivelina Minev, MSc; Boris Minev, MD; Aladar Szalay, PhD; | Immune suppression; NK/NK T cell; Solid tumors; T cell; Tumor evasion; Vaccine |
| P618 | Selective delivery of exosome-mediated STING agonist to antigen presenting cells results in significantly improved potency and reduced toxicity | Su Chul Jang, PhD; Raymond J. Moniz; Christine Sia; Joyoti Dey, Ph.D., M.P.H; Rane Harrison; NIKKI ROSS, PhD; Ke Xu; Kevin Dooley; Nuruddeen Lewis; Christine McCoy; Agata Villiger-Oberbek; Scott Estes; Jorge Sanchez-Salazar; Kyriakos Economides; Sriram Sathyanarayanan | Antigen presenting cells; Cytokine; Dendritic cell; Gene expression; Immune toxicity; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR |
| P619 | Image-guided intratumoral delivery of immunotherapeutics: interventional radiology perspective | Rahul A. Sheth, MD; Ravi Murthy, MD; Funda Meric-Bernstam, MD; David Hong, MD; Sapna Patel, MD; Alda Tam; | Clinical study; Immune adjuvant; Solid tumors; Targeted therapy |
| P620 | Enhanced efficacy and combinability of low dose toca 511 and 5-FC with metronomic chemotherapy in preclinical models | Sophie Viaud; Derek Ostertag; | Chemotherapy; Targeted therapy |
| P621 | Local immunotherapy with a mixture of mRNAs encoding pro-inflammatory cytokines promotes potent anti-tumor immunity and tumor eradication across multiple preclinical tumor models. | Timothy Wagenaar; Christian Hotz; Friederike Gieseke; Hui Cao; Jan Diekmann; Mustafa Diken; Christian Grunwitz; Andrew Hebert; Karl Hsu; Marie Bernardo; Katalin Kariko, PhD; Sebastian Kreiter; Andreas N. Kuhn; Mikhail Levit; Natalia Malkova; Serena Masciari, MD, MSc; Jack Pollard; Hui Qu; Abderaouf Selmi; Julia Schlereth; Fangxian Sun; Bodo Tillmann; Tatiana Tolstykh; Lena Wicke; Sonja Witzel; Qunyan Yu; Yu-An Zhang; Gang Zheng; Gary Nabel; Joanne Lager; Ugur Sahin, MD; Dmitri Wiederschain | Checkpoint blockade; Cytokine; Inflammation; Tumor microenvironment; Vaccine |
| P622 | Phase 1/2 evaluation of intratumoral INT230-6 for the treatment of solid tumors | Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, M.S., M.A, M.B.A.; Ian B. Walters, MD; Diana Hanna, MD; Jacob Thomas, MD; Lillian Siu, MD; Anthony El-Khoueiry, MD | Antigen presenting cells; Chemotherapy; Clinical trial; Dendritic cell; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P623 | The oncolytic peptide LTX-315 promotes natural killer cell recruitment and reduces lung metastatic burden in combination with local radiation therapy | Erik Wennerberg, PhD; Takahiro Yamazaki, PhD; Baldur Sveinbjornsson, PhD; Oystein Rekdal, PhD; Lorenzo Galluzzi, PhD; Sandra Demaria, MD; | Antigen presenting cells; Dendritic cell; NK/NK T cell; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P624 | Development of a STING agonist-producing synthetic Biotic™ medicine to activate innate and adaptive immunity and drive antitumor immune responses | Kip A. West, PhD; DANIEL LEVENTHAL, PHD; Ning W. Li, PhD; Christopher Plescia, MS; Starsha Kolodziej, BS; Rudy Christmas, BS; Carey Gallant, BS; Michael James, BS; Adam Fisher, PhD; Anna Sokolovska, PhD; Paul W. Miller, PhD; Jose M. Lora, PhD; Kip A. West, PhD; | Antigen presenting cells; T cell; Tumor microenvironment |
| O43 | Characterization of anti-tumor immune responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in spontaneous Osteosarcoma | Shruthi Naik, PhD; Kelly Makielski, DVM, MS; Michael Henson, DVM, PhD; Kathleen Stuebner; Alexander-Flaviu Tabaran, DVM, MSc, PhD; Ingrid Cornax, PhD; Gerard O'Sullivan, MVB, PhD; Andrea Eckert; Lauren Mills, PhD; Milcah Scott, BS; Aaron L. Sarver, PhD; Michael A. Farrar; Stephen J. Russell, MD, PhD; Jaime F. Modiano, VMD, PhD | Biomarkers; Immune monitoring; Pediatric tumors |
